Author/Authors :
Ghanbarzamani, Amirhossein Department of Clinical Pharmacy - Faculty of Pharmacy - Mazandaran University of Medical Sciences - Mazandaran, Iran , Salehifar, Ebrahim Department of Clinical Pharmacy - Faculty of Pharmacy - Mazandaran University of Medical Sciences - Mazandaran, Iran , Jafarirad, Abdolreza Department of Surgery - Zare Psychiatry and Burn Hospital - Mazandaran University of Medical Sciences - Sari, Iran , Hesamirostami, Mohammad Hossein Department of Surgery - Zare Psychiatry and Burn Hospital - Mazandaran University of Medical Sciences - Sari, Iran , Bagherzadehsaba, Ali Department of Surgery - Zare Psychiatry and Burn Hospital - Mazandaran University of Medical Sciences - Sari, Iran , Saeedi, Majid Department of Pharmaceutics - Faculty of Pharmacy - Mazandaran University of Medical Sciences - Sari, Iran , Ghazaeian, Monireh Department of Clinical Pharmacy - Faculty of Pharmacy - Mazandaran University of Medical Sciences - Mazandaran, Iran , Khorasani, Ghasemali Department of Plastic Surgery - Imam Khomeini Hospital - Tehran University of Medical Science - Tehran, Iran , Moosazadeh, Mahmood Health Sciences Research Center - Addiction Institute - Mazandaran University of Medical Sciences - Sari, Iran
Abstract :
As a common intervention among burn patients, skin graft has some risks such as infections
and delay of wound healing. The aim of this study was to assess the efficacy and safety of topical
0.25% Timolol Gel (TG) in promoting wound healing in split-thickness skin graft donor sites.
We conducted a double-blind, randomized clinical trial to assess re-epithelialization time, the
level of pain based on the Visual Analog Scale (VAS), and the wound infection incidence. The
scar status was also evaluated by the Vancouver Scar Scale (VSS) and the Patient and Observer
Scar Assessment Scale (POSAS). Totally, 64 patients were randomly assigned to the study groups.
The two groups showed a significant difference in healing time (14.5 ± 3.2 vs. 11.5 ± 2.3 days, P
< 0.001). No infection occurred in either group, and 3 cases of transplant rejection were observed
in the placebo group. The VAS was significantly different on days 1, 2, 3, 4, and 7 (P < 0.05). In
the third month, the results showed a significant difference in terms of VSS (P = 0.005). Topical
TG, due to its favorable effects on wound healing and pain reduction, can be administered as a
therapeutic agent in patients with a skin graft.
Keywords :
Burn , Wounds , Efficacy , Epithelization , Beta-blockers
